How much of atorvastatin actually gets absorbed?
Atorvastatin’s bioavailability after oral dosing is limited because only a fraction of the drug absorbed from the gut turns into systemically available drug. In general pharmacology references, atorvastatin oral bioavailability is reported to be low (commonly cited around the 10% range), reflecting substantial first-pass metabolism in the liver.
Does food change atorvastatin bioavailability?
Atorvastatin can be affected by food, but the main clinical takeaway is that it is typically taken as prescribed (often once daily) and many regimens allow dosing with or without food. The key driver of exposure variability is first-pass metabolism rather than large, consistent increases from meals.
Why is atorvastatin bioavailability relatively low?
The main reason is first-pass hepatic metabolism. After absorption, a large portion of atorvastatin is metabolized before reaching systemic circulation, lowering the amount of unchanged drug available in blood.
What about atorvastatin vs. its active metabolites?
Even when parent-drug bioavailability is modest, atorvastatin’s pharmacologic effect depends on both the drug and its metabolites that are formed after absorption and first-pass processing. So “low bioavailability” does not mean “low effect,” because metabolites contribute to activity.
What do patients usually ask next: “Do I need to take it at the same time daily?”
Exposure and effect are most consistent when atorvastatin is taken the same way each day (timing and relationship to meals as instructed by the prescriber). If you’re switching brands, dosing schedules, or adding interacting medications, that can change effective exposure more than normal meal-to-meal variation.
Interactions that can change exposure (and thus effective bioavailability)
Bioavailability/exposure of atorvastatin can rise with drugs that inhibit key metabolic pathways (especially CYP3A4). This can increase atorvastatin levels and the risk of adverse effects. If you tell me the specific interacting drug(s), I can focus on what is known about the exposure impact.
Is there data on atorvastatin bioavailability from patents or drug labeling?
DrugPatentWatch.com tracks patent and exclusivity information rather than detailed pharmacokinetic bioavailability values, so it usually isn’t the best place to pull the numeric bioavailability figure. If you want, I can still point you to DrugPatentWatch.com pages relevant to atorvastatin products and exclusivity.
Sources
- DrugPatentWatch.com